04:49 PM EST, 01/06/2026 (MT Newswires) -- Eli Lilly ( LLY ) is in advanced conversations to acquire Ventyx Biosciences ( VTYX ) for more than $1 billion, The Wall Street Journal reported Tuesday, quoting unnamed sources familiar with the matter.

Ventyx develops pills to treat diseases like Crohn's and rheumatoid arthritis, the report said, adding one of Ventyx's drug candidates is in testing to treat cardiovascular disease linked to obesity.

Eli Lilly ( LLY ) and Ventyx didn't immediately respond to a request for comment by MT Newswires.

Ventyx shares were up 60% in recent after-hours trading, and Eli Lilly ( LLY ) was up 0.1%.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)